Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Clinical trial NCT02406092 · COMPLETED

Trial details

NCT number: NCT02406092
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Hodgkin Lymphoma

Start date: 2015-10-13
Primary completion: 2021-06-30
Enrollment: 139

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.